Avigen's Gene Therapy Approach Shows Promise In Treating Hemophilia B With,,Single Intramuscular Administration

Long-Term Factor IX Expression and Improved Blood Clotting Time Achieved

SEATTLE, WASHINGTON (May 28, 1998): Scientists at Avigen, Inc. (Nasdaq: AVGN), and The Children's Hospital of Philadelphia have developed a gene therapy approach for the treatment of hemophilia B using a single intramuscular administration of an adeno-associated virus (AAV) vector containing the gene for coagulation factor IX. Katherine A. High, M.D., a hematologist at The Children's Hospital of Philadelphia and Avigen scientific advisor, will present research at the inaugural meeting of the American Society of Gene Therapy that shows the ability of AAV-mediated gene therapy to achieve sustained production of factor IX resulting in improved blood clotting times in a large animal model of hemophilia B.

"These results are very exciting, and can validate that AAV vectors in this model can provide sustained and long-term expression--something that other gene therapy systems have had limited success demonstrating," said John Monahan, Ph.D., president and chief executive officer of Avigen, Inc. "Based on these results and additional R&D advances at Avigen, we are working closely with Dr. High to develop this therapy further with the objective of initiating a human clinical trial as early as the end of calendar 1998 which, if successful, will represent a major advance in the treatment of hemophilia B."

"Our work extends previous results obtained in mice to a well-defined, naturally occurring, large animal model of hemophilia B that is very similar to the disease in humans," commented Dr. High. "This is the first example of the intramuscular administration of a gene therapy vector resulting in sustained improvement of the clotting abnormality in hemophilia and is an important step in justifying this approach for the treatment of patients with hemophilia B."

A single intramuscular administration of an AAV vector containing the gene for factor IX was given. The animals showe

Contact: Joan Kureczka
Kureczka/Martin Associates

Page: 1 2 3

Related biology news :

1. 1st International Conference on Cell Therapy for Cardiovascular Disease
2. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
3. Braunschweig Prize 2003 for Molecular Cancer Therapy
4. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
5. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
6. Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find
7. Invitation To Cover: American Society Of Gene Therapy Meeting
8. Gene Therapy For Pain
9. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
10. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils
11. Penn Researchers Develop Gene Therapy Technique That Reverses Muscle Membrane Weakness In Muscular Dystrophy Variant

Post Your Comments:

(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
Breaking Biology Technology:
Cached News: